Clinical trial
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected…
NCT02501096 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT02501096 |
|---|---|
| Title | A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors |
| Official title | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors |
| Lead sponsor | Eisai Inc., Industry |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | Lenvatinib, Pembrolizumab |
| Enrollment | 357 |
| Start date | Jul 22, 2015 |
| Primary completion | Aug 18, 2020 |
| Completion | Jul 11, 2022 |
| First posted | Jul 17, 2015 |
| Last update posted | Jul 20, 2023 |
| Countries | Norway, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: